Related Experiment Videos
Complement activation in patients with systemic lupus erythematosus without nephritis
T E Mollnes1, H J Haga, J G Brun
1Department of Immunology and Transfusion Medicine, Nordland Central Hospital, Bodø, Norway.
Rheumatology (Oxford, England)
|October 27, 1999
Summary
Complement activation products show limited value in monitoring systemic lupus erythematosus (SLE) without nephritis. However, the terminal complement complex (TCC) may indicate disease activity flares.
Area of Science:
- Immunology
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and damage to various organs.
- Complement activation is implicated in SLE pathogenesis, but its role in disease activity monitoring requires further investigation.
Purpose of the Study:
- To prospectively assess the association between disease activity and complement activation in SLE patients.
- To evaluate the utility of various complement activation products as biomarkers for SLE flares.
Main Methods:
- Prospective study of 21 SLE patients over one year.
- Monthly assessment of disease activity, autoantibodies, conventional complement tests, and complement activation products including C1rs-C1inh, C4bc, Bb, C3a, C3bc, C5a, and terminal complement complex (TCC).
Main Results:
- Disease activity showed modest variation; no patients had nephritis.
- Complement parameters remained relatively constant; decreased C4 levels were observed in several patients but not linked to increased activation.
- Terminal complement complex (TCC) was the only activation product significantly correlating with disease activity scores during flares.
Conclusions:
- Complement activation tests have limited utility in routine monitoring of SLE patients without nephritis.
- Terminal complement complex (TCC) shows potential as a sensitive marker for SLE disease activity.